Symbols

MIST

Milestone·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MIST

Milestone Pharmaceuticals Inc.

A biopharmaceutical company that developing innovative cardiovascular medicines

Industry

Pharmaceutical

Established Date

Listing Date

05/09/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.milestonepharma.com

Security Type

Common stock

Office address

1111 Dr. Frederik-Phillips Boulevard Suite 420 Montreal Quebec CA H4M 2X6

Business

Introduction

Milestone Pharmaceuticals Inc., was incorporated under the laws of Quebec in July 2003. The company is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular drugs. The company's approved product, CARDAYSTTM (Eltrapamil) nasal spray, is marketed in the United States and is the first and only self-therapeutic drug approved by the U.S. Food and Drug Administration for use by patients anytime, anywhere. The company continues to seek marketing approval from regulators responsible outside the United States, either directly or through cooperation with partners. The company is also developing Eltropamil, or "AFib-RVR," for the rapid ventricular rate atrial fibrillation indication.

Company Financials

EPS

MIST has released its 2025 Q4 earnings. EPS was reported at -0.16, versus the expected -0.16, meeting expectations. The chart below visualizes how MIST has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

MIST has released its 2025 Q4 earnings report, with revenue of 1.55M, reflecting a YoY change of NaN%, and net profit of -17.41M, showing a YoY change of -40.82%. The Sankey diagram below clearly presents MIST's revenue sources and cost distribution.